Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Due to the emergence of new anticancer agents for the treatment of ovarian cancer, methods to determine which agents will be most effective in individual patients are required. In order to investigate the potential for tailor-made chemotherapy, the drug sensitivities of various ovarian cancers were examined using collagen gel droplet embedded culture drug sensitivity testing (CD-DST), and the results were correlated with clinical outcomes. Sensitivities to paclitaxel, cisplatin, doxorubicin, etoposide, and SN-38, which is an active metabolite of irinotecan, were examined. Eight out of 22 samples failed to grow colonies and thus, their cell sensitivities could not be determined. Out of the 14 cases from which CD-DST results were obtained, seven patients then received chemotherapy aimed at inducing remission, while four received adjuvant, and three did not receive any chemotherapy. Three of the four tumors subsequently treated with adjuvant chemotherapy showed sensitivity to TXL and CDDP on CD-DST analysis, while one did not. None of these patients experienced recurrent disease from 24 to 36 months. Five of the seven tumors subsequently treated with chemotherapy aimed at inducing remission showed sensitivity to the relevant anticancer agents upon CD-DST analysis, while two did not. Among the five cases that showed tumor cell sensitivity, three experienced complete responses, one achieved a partial response and one had progressive disease. For the remaining two cases that demonstrated tumor cell resistance, one had stable disease and one had progressive disease following chemotherapy. Thus, six out of the seven cases (85.7%) that received chemotherapy aimed at inducing remission had clinical outcomes in keeping with the results of CD-DST. In conclusion, CD-DST results reflect clinical outcomes and may be a useful means by which to select drugs to which ovarian cancer cells are chemosensitive.
Yabushita
Hiromitsu
H
Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute-cho, Aichi-gun, Aichi 480-1195, Japan. yab@aichi-med-u.ac.jp
Ohnishi
Masafumi
M
Komiyama
Megumi
M
Mori
Takeshi
T
Noguchi
Mari
M
Kishida
Tameko
T
Noguchi
Yasuyuki
Y
Sawaguchi
Keizo
K
Noguchi
Masayoshi
M
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018929:Cell Culture Techniques / Q000379:methods*; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000494:pharmacology; D019411:Clinical Laboratory Techniques; D003094:Collagen / Q000737:chemistry*; D018450:Disease Progression; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D005782:Gels / Q000737:chemistry; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000494:pharmacology; D004364:Pharmaceutical Preparations; D012008:Recurrence; D012074:Remission Induction; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005782:Gels; D004364:Pharmaceutical Preparations; D005047:Etoposide; D000077146:Irinotecan; D004317:Doxorubicin; D003094:Collagen; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin